DermaTools Biotech GmbH

Healing for chronic wounds

DermaTools Biotech GmbH is developing DermaPro®, a patented and innovative product based on a complex chemical synthesis and formulation for the local treatment of chronic wounds.

DermaPro® is a new, patented substance (DPOCL) for the treatment of chronic skin wounds. DermaPro® has proven its clinical efficacy in various clinical studies involving more than 600 patients with diabetic foot or ulcus cruris (leg ulcer).

DermaPro® is a new, patented substance (DPOCL) for the treatment of chronic skin wounds. DermaPro® has proven its clinical efficacy in various clinical studies involving more than 600 patients with diabetic foot or ulcus cruris (leg ulcer).

bioXXmed AG is currently involved in the development of DermaPro® with around 19.7 million euros in equity.

Great potential

in a global market

There are currently more than 530 million diabetics worldwide (International Diabetes Federation, 2022).An increase of 45% to 784 million patients is expected by 2045. In addition to a high estimated number of unreported cases, many of these patients experience secondary complications of the eyes, kidneys and skin such as diabetic foot syndrome, despite increasingly better medications. This occurs with a mean annual prevalence of 6%(Robert Koch Institute 2019). The incidence is approximately 2% worldwide (Grand View Research, 2022). This means that approximately 30-50 million people worldwide suffer from diabetic foot syndrome.

Currently, diabetic foot treatment costs are $4.4 billion worldwide, with a projected increase to $6.3 billion in 2030. Among chronic wounds (leg ulcers and pressure ulcers), this is the largest segment of chronic wounds.

Drug and physical wound care products currently on the market do not show a satisfactory therapeutic standard for diabetic foot syndrome. DermaPro® meets a market with a high "medical need" here.

Safe and tolerable

application

The clinical efficacy and safety of DermaPro® has been proven in controlled clinical studies. Patients with different wound sizes and durations were included. Clinical endpoints varied, an approach that is not uncommon in such studies (Gould et al., Wound Rep Reg., 2019).

Efficacy at the target dose of 1.2 mmol/l demonstrated in various studies in the diabetic foot i.a.:

> 50%

Reduction in wound area as well as earlier closure compared to control

in 76 %

of cases there was complete wound closure compared to 62% under saline (Indian Phase III study)

13 %

better efficacy than hydrocolloid in the parameter "complete wound closure".

Approval as a medical device is planned for 2023.

Sustainable

Investment

Approval as a medical product, offers many advantages for investors and ensures positive long-term returns:

1

Protection even after the patent has expired, since a referential approval (generic approval) is not possible

2

Numerous clinical studies prove the outstanding efficacy of DermaPro®.

3

Medical product manufacturers dominate the "wound management" market; with DermaPro® a new treatment principle enters the scene

EN

bioXXmed AG
Riedstrasse 2
64295 Darmstadt
Germany